It is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Reportedly, regulatory action by the USFDA has impacted several new approvals, thus affecting the company's business in various regions including the US that remains the single-largest pharma market globally.